Aerovate Therapeutics
(NASDAQ) AVTE
Aerovate Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$127.41M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
AVTE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Aerovate Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
55
CEO
Tom Frohlich, MBA
Website
www.jadebiosciences.comHeadquarters
Waltham, MA 02116, US
AVTE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-65%
Return on Capital
-28%
Return on Assets
-36%
Earnings Yield
N/A
Dividend Yield
14.67%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$113.54M
EBITDA
$113.54M
Operating Cash Flow
$94.69M
Capital Expenditure
$196.00K
Free Cash Flow
$94.89M
Cash & ST Invst.
$88.44M
Total Debt
$724.00K
Aerovate Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
-100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
4
N/A
Net Income
$67.58M
-1144.6%
EBITDA
$57.20M
-794.5%
Quarterly Fundamentals
Net Cash
$87.71M
+12.2%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$724.00K
N/A
Short Term Debt
$0.00
-100.0%
Return on Assets
-36.43%
N/A
Return on Invested Capital
-28.07%
N/A
Free Cash Flow
$17.28M
-56.4%
Operating Cash Flow
$17.27M
-56.4%